Literature DB >> 20407399

Drug rash, eosinophilia, and systemic symptoms syndrome: Two pediatric cases demonstrating the range of severity in presentation--A case of vancomycin-induced drug hypersensitivity mimicking toxic shock syndrome and a milder case induced by minocycline.

Amy E Vinson1, Elizabeth M Dufort, Matthew D Willis, Craig P Eberson, Joseph I Harwell.   

Abstract

BACKGROUND: Drug rash, eosinophilia, and systemic symptoms syndrome is a type of drug hypersensitivity reaction characterized by the clinical triad of skin eruption, fever, and internal organ involvement. Drug rash, eosinophilia, and systemic symptoms syndrome has rarely been reported in association with vancomycin or in the pediatric population. There have only been four pediatric case reports of drug rash, eosinophilia, and systemic symptoms syndrome and three cases of drug rash, eosinophilia, and systemic symptoms syndrome involving vancomycin published in the English literature to date. CASE REPORTS: We describe two pediatric cases of drug rash, eosinophilia, and systemic symptoms syndrome to illustrate the range in severity of presentation. The first case illustrates drug rash, eosinophilia, and systemic symptoms syndrome associated with vancomycin exposure in a 14-yr-old boy with Duchenne muscular dystrophy after posterior spinal fusion, whose clinical presentation was indistinguishable from toxic shock syndrome. The second case illustrates a milder and more typical presentation of drug rash, eosinophilia, and systemic symptoms syndrome in a 14-yr-old boy being treated with minocycline for acne. We also present a review of the literature relevant to this syndrome.
CONCLUSIONS: : Drug rash, eosinophilia, and systemic symptoms syndrome is relatively unknown among general pediatricians and pediatric intensivists and may potentially become more common with the increasing use of long-term medications in the pediatric population. Our cases demonstrate the importance of an awareness of drug rash, eosinophilia, and systemic symptoms syndrome among general pediatricians and pediatric intensivists because drug rash, eosinophilia, and systemic symptoms syndrome may present in any range of severity, from indolent illness to frank and refractory shock.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20407399     DOI: 10.1097/PCC.0b013e3181c5911a

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  6 in total

1.  DRESS with delayed onset acute interstitial nephritis and profound refractory eosinophilia secondary to Vancomycin.

Authors:  Paloma O'Meara; Rozita Borici-Mazi; A Ross Morton; Anne K Ellis
Journal:  Allergy Asthma Clin Immunol       Date:  2011-10-03       Impact factor: 3.406

2.  Two cases with HSS/DRESS syndrome developing after prosthetic joint surgery: does vancomycin-laden bone cement play a role in this syndrome?

Authors:  Müberra Devrim Güner; Semra Tuncbilek; Burak Akan; Aysun Caliskan-Kartal
Journal:  BMJ Case Rep       Date:  2015-05-28

3.  Diphenylhydantoin Induced DRESS Syndrome: A Case Report.

Authors:  Figen Leblebici; Özlem Soyal; Nevzat Mehmet Mutlu; Hatice Yağmurdur; Onur Karaca
Journal:  Turk J Anaesthesiol Reanim       Date:  2013-05-23

Review 4.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist.

Authors:  Marwan H Adwan
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.686

Review 5.  Case report: atypical presentation of vancomycin induced DRESS syndrome: a case report and review of the literature.

Authors:  Olivia Wilcox; Mohamed Hassanein; John Armstrong; Nader Kassis
Journal:  BMC Pulm Med       Date:  2017-12-28       Impact factor: 3.317

6.  Drug reaction with eosinophilia and systemic symptoms (DRESS) in children.

Authors:  Francesca Mori; Carlo Caffarelli; Silvia Caimmi; Paolo Bottau; Lucia Liotti; Fabrizio Franceschini; Fabio Cardinale; Roberto Bernardini; Giuseppe Crisafulli; Francesca Saretta; Elio Novembre
Journal:  Acta Biomed       Date:  2019-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.